EUROPE Issue 413 dated 20/09/2001

Lessons from the Bayer Case

Lobbyists for the drugs industry have learned something from the health crisis that obliged Bayer to withdraw its anti-cholesterol drug: shift legal responsibility to patients by informing them more about the medicine.

303 words/5.20 EUR

Access to this article is restricted
to subscribers and e-wallet users

New reader?
Why create an account?
  • Read free articles
  • Download a free edition
  • Create email notifications
  • Receive newsletters
  • Access exclusive documents

By continuing your visit to this site, you accept the use of cookies allowing us to adapt and enhance your experience.